Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
Maragos
W F
WF
Department of Neurology, University of Kentucky Medical Center, Lexington 40536-0284, USA.
Jakel
R J
RJ
Chesnut
M D
MD
Geddes
J W
JW
Dwoskin
L P
LP
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001692:Biological Transport; D003010:Clorgyline / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism*; D008314:Malonates / Q000633:toxicity; D008474:Medial Forebrain Bundle; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009574:Nitro Compounds; D016627:Oxidopamine / Q000633:toxicity; D011422:Propionates / Q000633:toxicity; D051381:Rats; D012642:Selegiline / Q000494:pharmacology; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000502:physiology*
D008314:Malonates; D008996:Monoamine Oxidase Inhibitors; D009574:Nitro Compounds; D011422:Propionates; D012642:Selegiline; D016627:Oxidopamine; C030290:malonic acid; D003010:Clorgyline; D001058:Apomorphine; C015392:3-nitropropionic acid; D004298:Dopamine